Flufenamic Acid

규격

530-78-9CAS 번호

208-494-1EC 번호

2-[3-(trifluoromethyl)anilino]benzoic acidIUPAC 명칭

C14H10F3NO2화학식

281.23 g/mol분자량

flufenamic acid; 530-78-9; Arlef; Fluphenamic acid; Achless; 2-((3-(Trifluoromethyl)phenyl)amino)benzoic acid; N-(3-Trifluoromethylphenyl)anthranilic acid; Acido flufenamico; Flufenaminsaeure; Meralen; 2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid; Acide flufenamique; 2-[3-(Trifluoromethyl)anilino]benzoic acid; CI 440; NSC-82699; Acidum flufenamicum; 2-[[3-(Trifluoromethyl)phenyl]amino]benzoic acid; CN-27,554; 3'-Trifluoromethyldiphenylamine-2-carboxylic acid; INF-1837; DTXSID7023063; Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-; Benzoic acid, 2-((3-(trifluoromethyl)phenyl)amino)-; 60GCX7Y6BH; N-(alpha,alpha,alpha-Trifluoro-m-tolyl)anthranilic acid; NSC-219007; CHEBI:42638; CI-440; CN-27554; DTXCID303063; Acid, Flufenamic; 2-(3-(trifluoromethyl)anilino)benzoic acid; flufenamic acid aluminium; RefChem:388982; M01AG03; 208-494-1; Fullsafe; Nichisedan; Tecramine; Paraflu; Parlef; Flufacid; Lanceat; Plostene; Parlif; Surika; Reumajust A; Ristogen; Sastridex; Ansatin; Fluore-200; ANT-1; TVX 916; INF 1837; MFCD00002422; C.I. 440; NSC 219007; 2-(3-Trifluoromethylanilino)benzoic Acid; N-[3-(Trifluoromethyl)phenyl]anthranilic acid; 2-((3-Trifluromethyl)phenyl)aminobenzoic acid; 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID; N-(m-Trifluoromethylphenyl)-2-aminobenzoic acid; CHEMBL23588; MLS000028563; Saal-F; NCGC00016490-06; CAS-530-78-9; SMR000059027; N-(3-Trifluoromethylphenyl)-anthranilic acid; WLN: QVR BMR CXFFF; FFA; F0909-0007; Flufenamicacid; N-(.alpha.,.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; Flufenaminsaeure [German]; Acido flufenamico [Italian]; FLF; CCRIS 5266; 2-[(3-Trifluromethyl)phenyl]aminobenzoic acid; N-[(3-Trifluoromethyl)phenyl]anthranilic acid; Acide flufenamique [INN-French]; Acido flufenamico [INN-Spanish]; Acidum flufenamicum [INN-Latin]; N-((m-Trifluoromethyl)phenyl)-2-aminobenzoic acid; N-[(m-Trifluoromethyl)phenyl]-2-aminobenzoic acid; N-[m-(Trifluoromethyl)phenyl]-2-aminobenzoic acid; SR-01000000241; EINECS 208-494-1; Anthranilic acid,.alpha.,.alpha.-trifluoro-m-tolyl)-; N-(.alpha.,.alpha.-Trifluoro-m-tolyl)anthranilic acid; UNII-60GCX7Y6BH; Flufenamic acid [USAN:INN:BAN:JAN]; BRN 1996069; flufenamic-acid; Prestwick_220; Arlef (TN); Spectrum_001257; 1bm7; Opera_ID_578; Prestwick0_000203; Prestwick1_000203; Prestwick2_000203; Prestwick3_000203; Spectrum2_000789; Spectrum3_001273; Spectrum4_000102; Spectrum5_000686; Etofenamate EP Impurity A; Epitope ID:613429; EC 208-494-1; Flufenamic acid (Standard); CBiol_001756; SCHEMBL17497; BSPBio_000185; BSPBio_001319; BSPBio_002866; CBDivE_012649; FLUFENAMIC ACID [MI]; KBioGR_000039; KBioGR_000424; KBioGR_002267; KBioSS_000039; KBioSS_001737; KBioSS_002268; 3-14-00-00905 (Beilstein Handbook Reference); MLS001148610; DivK1c_000581; FLUFENAMIC ACID [INN]; FLUFENAMIC ACID [JAN]; SPECTRUM1501015; SPBio_000898; SPBio_002106; FLUFENAMIC ACID [USAN]; BPBio1_000205; GTPL2447; orb1310228; FLUFENAMIC ACID [MART.]; SCHEMBL29356958; BCBcMAP01_000039; BDBM17636; HMS501N03; HY-B1221R; KBio1_000581; KBio2_000039; KBio2_001737; KBio2_002267; KBio2_002607; KBio2_004305; KBio2_004835; KBio2_005175; KBio2_006873; KBio2_007403; KBio3_000077; KBio3_000078; KBio3_002366; KBio3_002747; Anthranilic acid, N-(alpha,alpha,alpha-trifluoro-m-tolyl)-; FLUFENAMIC ACID [WHO-DD]; MSK8002; cMAP_000004; NINDS_000581; Bio1_000042; Bio1_000531; Bio1_001020; Bio2_000039; Bio2_000519; Flufenamic acid (JAN/USAN/INN); GLXC-27023; HMS1361B21; HMS1568J07; HMS1791B21; HMS1921B21; HMS1989B21; HMS2089E07; HMS2092B09; HMS2095J07; HMS2232G24; HMS3371F01; HMS3402B21; HMS3652F06; HMS3712J07; HMS3885P15; HMS5082J22; Pharmakon1600-01501015; SMSSF-0062312; HY-B1221; NSC82699; Tox21_110452; Tox21_302111; CCG-40167; EBC-04210; MSK8002-100A; NSC219007; NSC757823; s4268; SBB001140; STK985630; AKOS000265536; MSK8002-1000A; Tox21_110452_1; CS-4811; DB02266; FF23323; KS-1143; NSC-757823; Etofenamate EP Impurity A (Free Base); IDI1_000581; IDI1_033789; NCGC00016490-01; NCGC00016490-02; NCGC00016490-03; NCGC00016490-04; NCGC00016490-05; NCGC00016490-07; NCGC00016490-08; NCGC00016490-09; NCGC00016490-10; NCGC00016490-12; NCGC00023200-03; NCGC00023200-04; NCGC00023200-05; NCGC00023200-06; NCGC00023200-07; NCGC00255175-01; CN-27544; ST026563; SY014664; SBI-0051633.P002; DB-052254; 2-[3-(trifluoromethyl)anilino]-benzoic acid; AB00052198; ETOFENAMATE IMPURITY A [EP IMPURITY]; F4483; n-(a,a,a-trifluoro-m-tolyl)anthranilic acid; NS00000475; SW196528-3; UNM000001246003; 2-[3-(Trifluoromethyl)anilino]benzoic acid #; EN300-16858; o-[m-(trifluoromethyl)phenylamino]benzoic acid; 2-[(3-Trifluoromethylphenyl)amino]benzoic Acid; D01581; D97458; AB00052198-14; AB00052198_15; F358173; Q416341; 3'-Trifluoromethyldiphenylamine-2-carbox ylic acid; Flufenamic acid Solution in Acetonitrile, 100ug/mL; SR-01000000241-2; SR-01000000241-3; BRD-K44067360-001-06-3; BRD-K44067360-001-16-2; BRD-K44067360-001-29-5; BRD-K44067360-001-30-3; Flufenamic acid Solution in Acetonitrile, 1000ug/mL; Z56797275; Flufenamic acid, analytical standard, for drug analysis; Anthranilic acid, N-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-; FFA, Flufenamic acid, 3-[(2-Carboxyphenyl)amino]benzotrifluoride, 2-Carboxy-3'-(trifluoromethyl)diphenylamine동의어